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Abstract
 
Clonal composition and T cell receptor (TCR) repertoire of CD4
 
1
 
 and CD8
 
1
 
 T cells infiltrat-
ing actively demyelinating multiple sclerosis (MS) lesions were determined with unprecedented
resolution at the level of single cells. Individual CD4
 
1
 
 or CD8
 
1
 
 T cells were isolated from fro-
zen sections of lesional tissue by micromanipulation and subjected to single target amplification
of TCR-
 
b
 
 gene rearrangements. This strategy allows the assignment of a TCR variable region
(V region) sequence to the particular T cell from which it was amplified. Sequence analysis re-
vealed that in both cases investigated, the majority of CD8
 
1
 
 T cells belonged to few clones.
One of these clones accounted for 35% of CD8
 
1
 
 T cells in case 1. V region sequence compar-
ison revealed signs of selection for common peptide specificities for some of the CD8
 
1
 
 T cells
in case 1. In both cases, the CD4
 
1
 
 T cell population was more heterogeneous. Most CD4
 
1
 
 and
CD8
 
1
 
 clones were represented in perivascular infiltrates as well as among parenchymal T cells.
In case 2, two of the CD8
 
1
 
 clones identified in brain tissue were also detected in peripheral
blood. Investigation of the antigenic specificities of expanded clones may help to elucidate their
functional properties.
Key words: autoimmunity • demyelinating disease • T cell receptor 
 
b
 
 chain • gene 
rearrangement • peripheral blood
 
Introduction
 
Multiple sclerosis (MS)
 
1
 
 is an inflammatory demyelinating
disease of the central nervous system that is generally be-
lieved to be of autoimmune origin. Destruction of myelin
sheaths leads to the formation of demyelinated lesions in
brain and spinal cord white matter (WM), which is associ-
ated with impaired nerve conduction and axonal loss re-
sulting in neurological disability. In most cases, MS initially
presents as a relapsing-remitting disease. However, with
time, a majority of patients enter a secondary progressive
course characterized by gradual clinical deterioration (1, 2).
While destruction of WM is ongoing, the lesions are histo-
logically characterized by dense infiltrates of macrophages
and T lymphocytes. These cells are found in dense aggre-
gates around postcapillary venules, but are also scattered
throughout the affected parenchyma (3, 4). Even after my-
elin destruction has ceased, infiltrates may persist for
months to years (3, 5). At later stages, a glial scar may result
with little or no signs of inflammation.
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Large CD8
 
1
 
 T Cell Clones in Multiple Sclerosis Lesions
 
The etiology of MS remains enigmatic. Various clinical
subtypes of the disease and distinct histopathological pat-
terns have been described, indicating that MS may also be
heterogeneous with respect to pathogenesis (3). Both envi-
ronmental and genetic factors play a role (1, 2, 6). Using
animal models of experimental autoimmune encephalomy-
elitis (EAE), it has been demonstrated that T cells, macro-
phages, and autoantibodies can contribute to immune-medi-
ated myelin injury (4, 7, 8). However, disease-initiating
roles of the various effector arms of the immune system re-
main to be proven in MS. Autoreactive T cells have been
implicated in the pathogenesis, and several myelin but also
nonmyelin antigens have been discussed as potential targets
of an autoimmune attack (6, 9). Oligoclonal expansions
of CD4
 
1
 
 T cells were detected in cerebrospinal fluid (CSF
[10, 11]), and an increased frequency of oligoclonal CD8
 
1
 
T cells expressing particular TCR-V
 
b
 
 gene segments were
found in the blood of MS patients compared with normal
controls (12).
Only limited information is available on the nature of T
cells in MS lesions. The T cell infiltrates are mainly com-
posed of TCR-
 
a
 
/
 
b
 
1
 
CD4
 
1 
 
and TCR-
 
a
 
/
 
b
 
1
 
CD8
 
1
 
 as well
as TCR-
 
g
 
/
 
d
 
1
 
 T cells in variable proportions (4, 13). Sev-
eral earlier studies have analyzed the TCR-
 
a
 
/
 
b
 
 repertoire
expressed in the lesions. By amplification of TCR gene re-
arrangements from reverse-transcribed mRNA extracted
from whole tissue specimens, Wucherpfennig et al. (14)
described polyclonal T cell populations contained in the
lymphocytic infiltrate. Using similar approaches, other
studies provided evidence for a restriction of the TCR rep-
ertoire expressed by infiltrating T cells (15–17). However,
in these studies, sequence data could not be assigned to ei-
ther CD4
 
1
 
 or CD8
 
1
 
 T cells. Therefore, TCR repertoire
and clonal composition of the two subsets in MS lesions are
still unknown. Another unresolved question is whether the
T cells found within the destructed parenchyma differ in
clonal composition and function from the large fraction of T
cells aggregated around blood vessels, as suggested by results
with murine EAE (18, 19). Furthermore, little is known
about potential differences in the composition of T cell pop-
ulations in actively demyelinating versus inactive MS lesions.
This study addresses these questions by an analysis of
clonal composition and TCR repertoire of the T cell infil-
trate at the level of single cells. Individual CD4
 
1
 
 or CD8
 
1
 
T cells located in perivascular infiltrates or in the paren-
chyma of actively demyelinating lesions were micromanip-
ulated from tissue sections. Using a PCR-based technique
described previously (20), TCR-
 
b
 
 gene rearrangements
were amplified from these single T cells and directly se-
quenced. V region sequence analysis revealed the presence
of large clonal expansions primarily among CD8
 
1
 
 T cells
but also in the CD4
 
1
 
 subset.
 
Materials and Methods
 
Patients and Tissue Samples.
 
Brain samples of case 1 were ob-
tained from the Netherlands Brain Bank (Amsterdam, The Neth-
 
erlands). The female patient died of cachexia at age 35, having
suffered from relapsing-remitting and secondary-progressive MS
for 10 yr. She received corticosteroid- and anti-TNF medication
3 and 2 yr before death, respectively, but received neither corti-
costeroids, anti-TNF, nor immunosuppressants during the last
year of her life. Two blocks of periventricular WM frozen in liq-
uid nitrogen upon autopsy were analyzed (see Fig. 1). HLA
genotyping was performed in the group of Dr. Albert at the Lab-
oratory for Immunogenetics (Ludwig-Maximilians-University,
Munich, Germany) by sequencing (HLA-A [21]), -B [22], and
-C [23]), PCR with sequence-specific primers (HLA-DRB
[24], -DQB [25]), or DNA typing with sequence-specific oli-
gonucleotide probes (HLA-DQA [26]). The patient was typed
HLA-A
 
*
 
2402/
 
*
 
2601, HLA-B
 
*
 
1801/
 
*
 
39062, HLA-Cw
 
*
 
0701/
 
*
 
0702,
HLA-DRB1
 
*
 
0101/
 
*
 
0801, HLA-DQA1
 
*
 
0101/
 
*
 
0401, HLA-DQB1
 
*
 
0501/
 
*
 
0402.
Male patient 2 presented with recurrent episodes of left-sided
hemianopsia at the age of 49. Cranial magnetic resonance imaging
was indicative of a malignant glioma located in the right tem-
porooccipital WM. Subsequently, the lesion was completely re-
sected at the Department of Neurosurgery at the University of
Bonn (Bonn, Germany) 2 wk after the first occurrence of symp-
toms. Histopathologically, a large area of inflammatory demyeli-
nation compatible with an MS lesion was found. Examination of
CSF revealed the presence of oligoclonal immunoglobulins, further
supporting the diagnosis of a first manifestation of MS. Within the
following 3 yr (until submission of this manuscript), the patient
suffered two relapses. Follow-up magnetic resonance imaging
confirmed the occurrence of new demyelinated lesions. Brain tis-
sue was frozen in liquid nitrogen immediately after resection, and
blood was sampled 12 and 31 mo after surgery (6 and 17 mo after
first and second relapse, respectively). The patient received IFN-
 
b
 
1a from the time of the second relapse until submission of this
manuscript. He seems to be homozygous for the haplotype HLA-
A
 
*
 
0101, HLA-B
 
*
 
0801, HLA-Cw
 
*
 
0701, HLA-DRB1
 
*
 
0301, HLA-
DRB3
 
*
 
0101, HLA-DQA1
 
*
 
05, HLA-DQB1
 
*
 
0201, as only one
allele was detected for each of the loci analyzed. As this haplotype
is the most common in the Caucasian population, homozygosity
is not uncommon. He gave informed consent to the use of brain
material and blood for research purposes. In neither case was CSF
available for analysis.
 
Immunohistochemistry, Micromanipulation, and Cell Counting.
 
Se-
rial 10-
 
m
 
m–thick frozen sections were mounted onto glass
slides. Every 15 sections, 3 sections were stained for luxol fast
blue, Oil Red O (ORO), and hematoxylin and eosin according
to standard procedures. Demyelinating activity of MS lesions was
assessed by immunohistochemistry on acetone-fixed sections (27).
Presence of myelin oligodendrocyte glycoprotein (MOG) and
proteolipid protein (PLP) in macrophage endocytic vesicles and
the acute stage inflammatory marker 27E10 on the macrophage
surface indicates recent phagocytosis of myelin (3, 27–29).
ORO
 
1
 
 macrophages can be found in actively demyelinating le-
sions, but may still be detectable weeks to months after myelin
destruction has ceased (3, 5). Therefore, absence of ORO
 
1
 
 mac-
rophages suggests that the lesion was inactive for at least some
weeks before resection. The primary antibodies used were anti-
MOG, anti-PLP (30; both provided by Dr. S. Piddlesden, Uni-
versity of Cardiff, Cardiff, UK), and anti-27E10 (purchased from
BMA Biomedicals). Micromanipulation was performed on adja-
cent sections stained for CD8 (C8/144B; Dako), CD4 (MT310;
Dako), CD3 (rabbit anti–human CD3; Dako), and human glial
fibrillary acidic protein (GFAP, 6F2; Dako) as described (20, 31).
Staining for TCR-
 
a
 
/
 
b
 
1
 
 and TCR-
 
g
 
/
 
d
 
1
 
 T cells was done using 
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antibodies 
 
b
 
F1 (8A3; T Cell Diagnostics) and pan-
 
g
 
/
 
d
 
 (Immu
510; Coulter-Immunotech Diagnostics), respectively. Biotiny-
lated Fab fragments of a rabbit anti–mouse (E413; Dako) and a
swine anti–rabbit (E431; Dako) antibody were used as secondary
reagents.
Using hydraulic micromanipulators, cells were mobilized from
surrounding tissue and transferred into PCR tubes as published
(20, 31).
For determination of CD8
 
1
 
/CD4
 
1
 
 ratios, 300–800 positive
cells in the parenchymal and 100–400 positive cells in the perivas-
cular location were counted per subset on serial sections. CD4
 
1
 
cells displaying a macrophage morphology were excluded. In case
1, the CD8/CD4 ratio was determined in lesions 3 and 4 only, as
hardly any CD4
 
1
 
 but numerous CD8
 
1
 
 T cells were detected in
the parenchyma of lesions 1 and 2 (see Fig. 1 and legend to Table
II). In both cases, counting of CD8
 
1
 
 and CD4
 
1
 
 T cells in
perivascular infiltrates was hampered by the presence of CD4
 
1
 
macrophages and high cellular density. Therefore, these values
represent rough assessments.
 
Amplification of TCR-
 
b
 
 Gene Rearrangements from Single Cells.
 
TCR-V
 
b
 
 gene rearrangements were amplified by seminested
PCR as described (20), with minor modifications specified be-
low. In brief, a first round of amplification was performed using a
mix of 24 V
 
b
 
 gene family–specific and 8 J
 
b
 
-specific primers. In a
second round of PCR, two to three of the same V
 
b
 
 primers were
used together with a mix of seven internal J
 
b
 
-specific primers in
separate reactions. Compared with the primer mixes published
previously (20), the V
 
b
 
25 primer was omitted, a new nested
primer pair specific for J
 
b
 
2S3 (3
 
9
 
J
 
b
 
2S3: 5
 
9
 
-TCCCGGGGCGC-
CCCCTCCCCAGTT-3
 
9
 
 and 5
 
9
 
J
 
b
 
2S3: 59-GAGCCCCCGCT-
TACCGAGCACTGTCA-39) was employed, and the primers
Vb4, 39Jb2S7, and 59Jb2S7 were modified (Vb4: 59-TCCAGT-
GTCAAGTCGATAGCCAAGTC-39; 39Jb2S7: 59-TCCAT-
CGTTCACCTTCTCTCTAAACA-39; and 59Jb2S7: 59-GCC-
CGAATCTCACCTGTGACCGTG-39). Primers were purchased
from Eurogentec (first round primers were “single cell quality”).
Sequence Analysis. PCR products were gel purified from
2.5% agarose gels using the Qiaex® II gel extraction kit
(QIAGEN) and directly sequenced using the ABI PRISM Big-
Dye® Terminator Cycle Sequencing Ready Reaction Kit (Perkin-
Elmer) and an automatic sequencer (ABI 377, PerkinElmer). V
gene sequences were analyzed using DNASIS® software (Amer-
sham Pharmacia Biotech). Sequence data is available from
EMBL/GenBank/DDBJ under accession nos. A7405646–
A7405872.
Sorting of Peripheral Blood T Cells. For CDR3 spectratyping,
PBMCs were purified from blood samples of case 2 obtained 12
and 31 mo after brain surgery by density gradient centrifugation
using Ficoll-Paque (Amersham Pharmacia Biotech) and were
stained with fluorescein-conjugated anti-CD3 (SK7; Becton
Dickinson) and PE-conjugated anti-CD4 (MT310; Dako) or
PE-conjugated anti-CD8 (DK25; Dako). CD31CD41 or
CD31CD81 cells were sorted by FACS® using a FACS® 440
(Becton Dickinson) into Eppendorf tubes containing RPMI 1640
medium supplemented with 10% FCS. The tubes were cooled at
48C during the sorting procedure. Dead cells were excluded from
the analysis by staining with propidium iodide. PBMCs from
blood sample “12 mo” had been cryopreserved before staining
and sorting procedures. For clone-specific PCR, cryopreserved
PBMCs obtained from blood drawn 12 and 31 mo after brain
surgery were stained with PE-conjugated anti-CD8 and allophy-
cocyanin-conjugated anti-CD45RO (UCHL-1; Becton Dickin-
son) antibodies, and 102 or 103 CD81CD45RO1 cells were
sorted into each of several PCR tubes. For single cell PCR con-
trols, PBMCs were purified from blood of five healthy caucasian
donors and stained with fluorescence-labeled antibodies. Single
TCR-a/b1CD31 cells were sorted into PCR tubes by FACS®
as reported (20).
CDR3 Spectratyping of TCR-b Transcripts from Peripheral Blood
T Cells. Total RNA was prepared from 105 (sample “12 mo”),
and 2 3 105 (sample “31 mo”) CD31CD41 and CD31CD81
cells, oligo-(dT)-primed cDNA was reverse transcribed, and
CDR3 spectratype analysis was carried out as reported previously
(32). In brief, cDNA was subjected to TCR-Vb gene family–
specific PCR in 26 separate reactions, each containing 1 of 26 Vb
family– and 1 Cb-specific primer (12). Using 1 of 13 fluores-
cence-labeled Jb-specific oligonucleotides (33), runoff prod-
ucts were generated from each Vb-specific PCR product. Tran-
scripts were resolved on a sequencing gel, and fluorescence
intensities were measured with help of an automated DNA se-
quencer. Expanded candidate Vb-Jb subpopulations were sub-
amplified from the initial Vb-Cb amplification product using
Vb- and Jb-specific primers and were directly sequenced (32). A
sequence readable in CDR3 results if the population of TCR-b
mRNA molecules amplified by the Vb-Jb primer combination
was dominated by a single clonal transcript.
Cloning of PCR Products. The Vb14-Jb1S1 subpopulation
was subamplified from cDNA derived from CD31CD81 cells
with the respective Vb-Jb primer pair. 1 ng of the freshly ampli-
fied PCR product was cloned into pCR2.1 vector using the
Original TA Cloning® Kit (Invitrogen). Colonies were randomly
picked, and plasmid-DNA was purified using the QIAGEN Plas-
mid Mini Kit. Inserts were sequenced with the Vb14-specific
primer.
Generation of Jurkat Control Cells for Clone-specific PCR. To
establish and positively control clone-specific PCR (specific am-
plification of the V region sequences of clones 2, 3, and 8 identi-
fied in brain tissue of case 2), cells were generated that carried one
copy of either TCR-b gene rearrangement as a stable genomic
integration. Either rearrangement (PCR-product) was cloned
into the pRc/CMV vector (Invitrogen). Integrity of primer bind-
ing sites (see below) was verified by sequencing and linearized
vector (1 mg) was transfected into Jurkat cells (4 3 106; gift of Dr.
M. Schreier, Novartis, Basel, Switzerland) using DMRIE-C re-
agent (Life Technologies) according to the manufacturer’s in-
structions. Cells were seeded at 3 3 104 per well in 96-well plates
and selected with 1 mg/ml G418 (Geneticinâ; Life Technologies)
for 5 wk to obtain stable integrants. Clones carrying a single copy
of the transfected vector were identified by Southern blotting
(data not shown).
Clone-specific PCR. To determine efficiencies of clone-spe-
cific single target amplification (described above), even in a situa-
tion where only 1 of up to 103 cells carried the clonal target
sequence, single Jurkat control cells were sorted into tubes
containing 103 irrelevant TCR-a/b1CD31 T cells from a
healthy donor as described above. Upstream primers for V regions
for first and second round amplification were Vb4- (clone 2) and
Vb13-specific oligonucleotides (clones 3 and 8; described above).
Nested primers (external primers for first round and internal prim-
ers for second round amplification) specific for clonal CDR3 re-
gions were 59-GTCAGGACGTTGGCCCCAGAAA-39 (clone 2,
external), 59-AGGACGTTGGCCCCAGAAACCT-39 (clone 2,
internal), 59-CCGAAGAACTGCTCATTGTAGGTG-39 (clone 3,
external), 59-AGAACTGCTCATTGTAGGTGGCAA-39 (clone 3,
internal), 59-CCCGAAGAACTGCTCATTGTATTG-39 (clone 8,
external), and 59-GAAGAACTGCTCATTGTATTGCGC-39396 Large CD81 T Cell Clones in Multiple Sclerosis Lesions
(clone 8, internal). After incubation with 0.5 mg/ml proteinase K
(Life Technologies) for 2 h at 508C followed by heat inactivation
of the enzyme for 10 min at 958C, samples were subjected to
first-round amplification in the same reaction tube in 13 Ther-
mophilic DNA Polymerase Buffer (Promega); 100 mM each of
dATP, dGTP, dCTP, and dTTP; 42 nM of each primer; 1.5 mM
MgCl2 in case of clone 2– and clone 3–specific PCR or 2 mM
MgCl2 in case of clone 8–specific PCR; and 2.5 U Taq DNA
Polymerase in Storage Buffer A (Promega). An initial cycle of
958C for 2 min, a pause at 808C during which Taq was added,
708C for 30 s, and 728C for 50 s was followed by 34 cycles of
958C for 60 s, 708C for 30 s, and 728C for 50 s and a single 5-min
incubation step at 728C. Conditions for second-round amplifica-
tion were as follows: 20 mM Tris-HCl, pH 8.4; 50 mM KCl; 100
mM each of dATP, dGTP, dCTP, and dTTP; 150 nM of each
primer; 1.5 mM MgCl2 in case of clone 2– and clone 3–specific
PCR or 4 mM MgCl2 in case of clone 8–specific PCR; 1 ml first-
round reaction mixture; and 1.3 U Taq polymerase (Life Tech-
nologies) were subjected to 1 cycle of 958C for 2 min, 708C for
30 s, and 728C for 90 s followed by 44 cycles of 958C for 60 s,
708C for 30 s, and 728C for 60 s followed by 728C for 5 min.
When a single Jurkat control cell was analyzed together with 103
irrelevant T cells, 13 of 16, 13 of 16, and 13 of 25 such samples
were positive in the specific amplification of V-regions of clones
2, 3, and 8, respectively. In no instance was a specific product ob-
tained from samples of irrelevant T cells in the absence of a Jurkat
control cell. For each of the three clone-specific amplifications,
five arbitrarily chosen PCR products were sequenced; all repre-
sented the respective clonal sequence.
For analysis of blood samples of case 2, samples containing 102
or 103 CD81CD45RO1 cells (described above) were analyzed
by clone 2–, 3–, and 8–specific PCR in parallel with samples
containing Jurkat cells carrying the respective rearrangement (two
per tube) plus 102 or 103 CD81CD45RO1 T cells from a healthy
donor as positive controls. All PCR products obtained from test
samples were sequenced.
Results
Selection of Brain Material and Design of the Single Cell PCR
Analysis. To identify actively demyelinating MS lesions
in frozen sections of brain specimens, the molecular com-
position of myelin degradation products within macro-
phage vesicles (28, 29) and the expression of 27E10, an in-
flammatory macrophage activation antigen, were determined
by immunohistochemistry as described previously (3, 27).
Throughout this paper, lesions were considered “active” or
“actively demyelinating” if signs of recent myelin phagocy-
tosis and macrophage activation were detectable (described
in Materials and Methods). All other lesions were consid-
ered “inactive,” irrespective of the presence of inflamma-
tory infiltrates. In total, five lesions originating from two
MS cases were selected for single cell PCR analysis. Four
lesions were from autopsy material of case 1, including a le-
sion that was active over its entire area, an inactive lesion,
and two lesions showing active as well as inactive areas
(Fig. 1). A single lesion that showed signs of ongoing my-
elin destruction over its entire area was found in biopsy ma-
terial of case 2 (not shown). It likely represented an early
stage of lesion development, as the lesion was already re-
sected 2 wk after clinical manifestation of the disease. All
lesions contained large numbers of T cells located in
perivascular aggregates (subsequently termed “perivascular
cells”) or outside of these, scattered over the demyelinated
parenchyma as solitary cells (“parenchymal cells”). In le-
sions of both cases, CD81 T cells outnumbered CD41 T
cells by at least a factor of three (see legends to Tables II
and III).
To analyze CD41 and CD81 T lymphocytes infiltrating
active and inactive lesions for clonal composition and TCR
repertoire, sections adjacent to those used for the mapping
of lesional activity were stained for CD4, CD8, and CD3.
Single parenchymal CD41 or CD81 and a small number of
parenchymal CD31 T cells were micromanipulated and
transferred to PCR tubes. Within the perivascular infil-
trates, reliable identification of individual CD41 or CD81
cells was difficult because of dense aggregation of the cells
and leakage of the dye from positive cells into the sur-
rounding tissue. Furthermore, micromanipulation of single
cells from this location was hampered by the presence of
connective tissue. Therefore, instead of single CD41 and
CD81 cells, samples of 5–10 cells were micromanipulated
from perivascular infiltrates and transferred to PCR tubes
without paying attention to morphology or immunostain-
ing of individual cells. These samples were mainly com-
posed of T cells and macrophages.
TCR-b gene rearrangements were amplified from the
genomic DNA of micromanipulated single parenchymal
cells and samples of perivascular cells using a mixture of 25
Vb family– and 8 Jb-specific primers in the first of two
rounds of amplification as described (20). PCR products
were directly sequenced. Single astrocytes micromanipu-
lated from adjacent sections (immunostained for the astro-
cyte marker GFAP), aliquots of the buffer covering the sec-
tions during the micromanipulation procedure (“buffer
samples”), and water controls were analyzed in parallel as
controls for cellular or PCR product contamination (Table
I). Whereas, 229 of 798 single parenchymal cells (29%) and
86 of 140 samples of perivascular cells (61%) analyzed in to-
tal from both cases were positive for at least one specific
PCR product, none of the negative control samples yielded
a TCR gene rearrangement (Table I). The efficiency of
Figure 1. Schematic overview of sections of the two blocks of brain
tissue (A and B) analyzed for case 1. Nos. 1–4 designate MS lesions from
which T cells were micromanipulated. Hatched lesional areas show signs
of ongoing myelin destruction. Block A also contained an old lesion
(SCAR) showing astroglial scarring, and only a little infiltration by T cells
or other signs of inflammation.397 Babbe et al.
single target amplification of TCR-b gene rearrangements
was controlled by analysis of single TCR-a/b1CD31 cells
from blood of healthy donors sorted into PCR tubes by
FACS®. Specific products could be amplified from 66 of 90
of such single cells (73%; Table I). These products were all
unique and unrelated to those obtained from the microma-
nipulated cells. The results of the control amplifications are
in accordance with our previous data, which suggest that
the amplification of TCR-b gene rearrangements from sin-
gle cells is reliable with respect to unbiased amplification of
the majority of all possible rearrangements and the assign-
ment of sequences to individual cells (20; data not shown).
Additional evidence for the reliability of the combination
of micromanipulation and single cell PCR was derived
from the observation that rearrangements that had been ob-
tained from micromanipulated CD81 cells were never
found in CD41 cells or vice versa, although repeats were
frequent within both the CD41 and especially the CD81
compartment.
Oligoclonal Expansions Account for the Majority of CD81 T
Cells in Active and Inactive MS Lesions. Tables II and III
assign potentially functional TCR-b gene rearrangements
to the respective cell samples from which they had been
amplified (parenchymal CD41 and CD81 or perivascular
cells). Of the 81 single parenchymal CD81 T cells from
four different lesions of case 1 that yielded a potentially
functional TCR-b gene rearrangement, 28 were unique;
i.e., they were obtained from one particular cell sample
only (Table II). However, 53 sequences (65%) were com-
posed of 13 gene rearrangements, each of which was am-
plified from more than one cell, and therefore represented
an expanded CD81 T cell clone. One of these clones
(clone 1) was by far the most prominent. Its clonal rear-
rangement accounted for 28 of all 81 parenchymal CD81
T cells (35%). The remaining CD81 T cell clones were
represented between one and five times among the 81 pa-
renchymal CD81 cells.
To identify potential differences in clonal composition
and TCR repertoire between active and inactive lesions,
two lesions were compared. Lesion 2 exhibited signs of ac-
tive demyelination, and ORO1 macrophages throughout
the affected area, whereas lesion 1, although heavily infil-
trated by macrophages and T cells, was inactive (Fig. 1) and
ORO2 (described in Materials and Methods). The com-
parison was confined to the CD81 subset because, in con-
trast to a large number of CD81 cells, only very few CD41
T cells could be identified in these two lesions. The fre-
quency of clone 1 was about twofold higher in inactive le-
sion 1 compared with active lesion 2. The major CD81 T
cell clones (clones 1, 2, and 9) were found in lesion 1 as
well as in lesion 2. In lesion 1, 15 additional rearrangements
were obtained from CD31 cells. Like those derived from
CD81 T cells, the majority could be assigned to clonal ex-
pansions (10/15 [67%]). Only members of CD81 clones
were encountered (clone 1, 6/15 [40%]; clone 2, 3/15;
clone 19, 1/15).
The composition of CD81 T cells infiltrating lesions 3
and 4, both of which showed active as well as inactive areas
(Fig. 1), was similar to that of lesions 1 and 2. Clone 1 was
the most prevalent clone in all four lesions. Likewise,
members of most other clones were detected in at least two
lesions.
Among 24 rearrangements obtained from single paren-
chymal CD81 cells of case 2, 17 (71%) originated from 9
Table I. Summary of Single Cell PCR Analysis of T Cells Micromanipulated from MS Lesions of Cases 1 and 2
Samples analyzed
Positive for at least one
specific PCR product
Total no. of potentially 
functional rearrangements
Case 1 547 single parenchymal T cells 141/547 (26%) 133
107 samples of perivascular cells 60/107 (56%) 86
Case 2 251 single parenchymal T cells 88/251 (35%) 76
33 samples of perivascular cells 26/33 (79%) 46
Controls 90 micromanipulated GFAP1 astrocytes 0/90 —
90 buffer samples 0/90 —
90 water controls 0/90 —
90 single FACS®-sorted T cells 66/90 (73%) 58
Frozen sections of MS lesions were used to micromanipulate samples of 5–10 cells from perivascular infiltrates and single parenchymal T cells located
outside of perivascular infiltrates. TCR-b gene rearrangements were amplified from these samples. Single astrocytes micromanipulated from adjacent
sections, aliquots of the buffer covering the sections during the micromanipulation procedure, and control tubes containing PCR buffer but no cells
served as negative controls. Single T cells sorted from blood of healthy donors were used to control for the efficiency of single target amplification.
Among the 448 rearrangements that were amplified in total from micromanipulated and control T cells and for which the reading frame could be
unequivocally determined, 49 were nonfunctional (11%; i.e., either stop codon in CDR3, rearrangement of a pseudogene, or out-of-frame
rearrangement). As this study focused on the detection of potentially functional rearrangements, additional bands amplified from single cells that may
potentially represent nonfunctional rearrangements were not necessarily sequenced. Therefore, our results probably underestimate the prevalence of
nonfunctional rearrangements in human T cells. To exclude the possibility that a substantial number of rearrangements was derived from g/d instead
of a/b T cells (potentially functional TCR-b gene rearrangements were described in g/d T cells [reference 65]), adjacent tissue sections were stained
for TCR-g/d or -a/b. In both cases, g/d T cells accounted for ,3% of all T cells.398 Large CD81 T Cell Clones in Multiple Sclerosis Lesions
different clones, whereas only 7 sequences were unique
(Table III).
The Population of CD41 T Cells is more Heterogeneous than
the CD81 Population. 28 of 37 gene rearrangements am-
plified from parenchymal CD41 T cells of case 1 were
unique, whereas four rearrangements were obtained re-
peatedly and accounted for 9 of the 37 cells (24%; Table
II). In case 2, 46 of the 52 parenchymal CD41 T cells
could not be assigned to any clonal expansion, whereas 6
(12%) belonged to three clones (Table III). Thus, paren-
chymal CD41 T cells were more heterogeneous than pa-
renchymal CD81 T cells in both cases analyzed.
Most CD41 and CD81 Clones were Represented in Perivas-
cular Infiltrates As Well As Among Parenchymal T Cells. As
shown in Table II, 45% of the 86 potentially functional re-
arrangements amplified from samples of perivascular cells in
case 1 could be assigned to clonal expansions. The major
clones (more than three members detected) were all en-
countered in the parenchymal as well as in the perivascular
location.
Of the 46 sequences derived from perivascular cells in case
2, 26% could be assigned to clonal expansions. Except for
clone 5, the major clones (more than two members detected)
were also represented in both locations in this case (Table III).
Table II. Representation of CD41 and CD81 T Cell Clones in Perivascular and Parenchymal Locations of the Four Lesions Analyzed for 
Case 1
Single parenchymal CD81 T cells Single parenchymal CD41 T cells Samples of perivascular cells
Lesion Clone no. Frequency Clone no. Frequency Clone no. Frequency
No. 1 1 14/29 (48%) 1 8/41 (20%)
9 3/29 6 2/41
3, 4, 7, 15, 21 1/29 12 1/3 3, 4, 13,17 1/41
Sum: 22/29 (76%) Sum: 14/41 (34%)
No. 2 1 6/28 (21%)
2 3/28 1, 8 3/25
9 2/28 2 2/25
3, 16, 18, 19 1/28 11 1/2 7, 10 16, 21 1/25
Sum: 15/28 (54%) Sum: 12/25 (48%)
No. 3 1 8/24 (33%) 1 4/14
16, 18 2/24 10, 11 2/19 4 2/14
4, 14, 15, 17 1/24 12, 13 1/19 9, 14 1/14
Sum: 16/24 (67%) Sum: 6/19 (32%) Sum: 8/14
No. 4 1 3/6
10 1/13 9, 15 1/6
Sum: 5/6
Sum 1 28/81 (35%)
9 5/81 1 18/86 (21%)
2, 16, 18 3/81 10, 11 3/37 4, 8 3/86
3, 4, 15 2/81 12 2/37 2, 6, 9 2/86
7, 14, 17, 19, 21 1/81 13 1/37 3, 7, 10, 13, 14, 15, 16, 17, 21 1/86
Sum: 53/81 (65%) Sum: 9/37 (24%) Sum: 39/86 (45%)
Clonal expansions were identified by amplification of an identical rearrangement from at least two different samples of cells micromanipulated from
material of case 1, and were numbered arbitrarily. Except for clones 6 and 8, all clones could be assigned to the CD81 or CD41 subset, as the clonal V
region sequence was obtained at least once from a single parenchymal CD81 or CD41 cell. Only potentially functional rearrangements are listed. Three
clones defined by nonfunctional rearrangments accounted for 7 of the 24 nonfunctional rearrangments obtained in total. These clonal sequences could
not be assigned to clones defined by potentially functional rearrangements. The population of parenchymal T cells was dominated by CD81 T cells (CD8/
CD4 < 3, as determined in lesions 3 and 4). Likewise, perivascular CD81 T cells outnumbered perivascular CD41 T cells roughly by a factor of three.399 Babbe et al.
V Region Sequences of Some CD81 T Cells in Case 1
Showed Signs of Selection for Common Antigenic Specificities.
Potentially functional TCR-b gene rearrangements were
analyzed for similarities of deduced CDR3 amino acid se-
quences and biased Vb or Jb gene segment usage, which
might suggest selection for recognition of common
epitopes. Analysis of CDR3 sequences of case 1 revealed
that the V region amino acid sequence of CD81 clone 7
was identical to an unique rearrangement amplified from
perivascular sample A278 (Table IV). This finding of
clonally independent T cells (nucleotide sequences shown
in Table IV) with identical b chains within a limited num-
ber of cells strongly suggests that these cells were engaged
in a response against the same epitope. Dominant clone 1
shared part of the NDN-encoded amino acid sequence
motif (SGSG) of this b chain in the same position relative
to the conserved cysteine of the Vb segment, whereas
unique sequence H518 shared all four amino acids. No re-
current CDR3 amino acid motifs were found in the se-
quences obtained from the remaining CD81 or CD41 T
cells or from T cells from case 2.
16 of 37 CD41 T cells (43%) amplified from case 1 har-
bored a potentially functional rearrangement incorporating
Jb1S1. Among unselected T cells from healthy individuals,
only 9–15% have been reported to express rearrangements
of this Jb gene segment (34, 35). Likewise, a control col-
lection of 196 potentially functional gene rearrangements
from peripheral blood of five healthy donors (20; this
study, and data not shown) contained only 12% of rear-
rangements of Jb1S1. Except for the overrepresentation of
Jb1S1 in rearrangements from CD41 T cells of case 1, the
distribution of Vb and Jb gene segments resembled that
determined in the control collection in both cases analyzed,
thus providing no further evidence that the micromanipu-
lated cells were sampled from an antigen-selected popula-
tion.
In Case 2, a CD81 Clone Identified in Brain Tissue Was
Also Detected in Blood Samples Obtained 12 and 31 mo after
Brain Biopsy by CDR3 Spectratyping. Two blood samples
of case 2 obtained 12 and 31 mo after surgical removal of
the lesion were available. To determine whether clonal ex-
pansions of T cells identified in the brain lesion were also
encountered at a high frequency in peripheral blood T
cells, and thus may in principle be amenable to isolation
and cloning procedures, CDR3 spectratyping (Immuno-
scope) analyses were carried out. This PCR-based tech-
nique allows examination of length distributions in TCR-b
transcripts from PBMCs, and thereby detection of ex-
panded T cell clones. Clonal expansions stand out as prom-
inent peaks from the overall CDR3 length distribution
obtained for polyclonal T cell populations (36). This
Table III. Representation of CD41 and CD81 T Cell Clones in 
Perivascular and Parenchymal Locations of the Single Lesion Analyzed 
for Case 2
Single parenchymal 
CD81 T cells
Single parenchymal 
CD41 T cells
Samples of perivascular 
cells
Clone no. Frequency Clone no. Frequency Clone no. Frequency
2 4/24 (17%)
5 3/24 8 3/46 (7%)
3, 6, 9 2/24 1, 2, 7 2/46
4, 8, 7, 10 1/24 13, 14, 15 2/52 3, 4, 10 1/46
Sum: 17/24 (71%) Sum: 6/52 (12%) Sum: 12/46 (26%)
Clonal expansions were identified by amplification of an identical rear-
rangement from at least two different samples of cells micromanipulated
from material of case 2, and were numbered arbitrarily. Except for
clone 1, all clones could be assigned to the CD81 or CD41 subset, as
the clonal V region sequence was obtained at least once from a single
parenchymal CD81 or CD41 cell. Only potentially functional rear-
rangments are listed. One clone defined by a nonfunctional rearrange-
ment accounted for 2 of the 17 nonfunctional rearrangements obtained
in total. This clone could not be assigned to a clone defined by a poten-
tially functional rearrangement. Within the parenchyma, CD81 T cells
outnumbered CD41 T cells by a factor of five to six, and roughly by a
factor of three in the perivascular location.
Table IV. Case 1: CDR3 Nucleotide and Deduced Amino Acid Sequences of TCR-b Gene Rearrangements Amplified from 
Micromanipulated T Cells
Clone/sample Vb V NDN* JJ b CDR3 length
A278 11S1 C A  S S E  S G S G E K  L F  F G 1S4 10
TGTGCCAGCAGTGAA TCCGGATCTGGC GAAAAACTGTTTTTTGGC
7 11S1 C A  S S E  S G S G E K  L F F G 1S4 10
TGTGCCAGCAGTGAA AGTGGGTCGGGG GAAAAACTGTTTTTTGGC
1 6S5 C  A  S S L  SG  Q G D Y G Y T F G 1S2 11
H518 13S3 C A T G V  S  G S G G E Q F F G 2S1 10
Sequences A278 and H518 were both amplified from samples of perivascular cells (CD81 clones 1 and 7 are introduced in Table II). CDR3 sequences
are shown from the conserved cysteine of the Vb to the conserved FG motif of the Jb elements. Amino acids of the common SGSG motif are shown
in bold. CDR3 lengths definition was as in Moss and Bell (reference 66).
*Amino acids encoded by N and P nucleotides and the D elements in the hypervariable V-J junction.400 Large CD81 T Cell Clones in Multiple Sclerosis Lesions
technique can detect clonal T cell populations among
polyclonal T cells with a sensitivity of z1 in 5 3 103 de-
pending on the clonal CDR3 length and the primer com-
bination used (32, 37).
FACS®-sorted CD41 and CD81 T cells were investi-
gated. A prominent peak in the spectragram of the Vb14-
Jb1S1 subpopulation of CD81 T cells was shown (by clon-
ing of the PCR product and sequencing of plasmid DNA
from bacterial colonies) to reflect the presence of CD81
clone 10 (Table III) in peripheral blood T cells at both time
points analyzed (Fig. 2). No other clonal rearrangement
identified in the brain sections was detected in blood sam-
ples by the spectratyping technique.
A Second CD81 Clone Identified in Brain Tissue Was Also
Detected in Blood Samples of Case 2 by Clone-specific PCR.
In a second approach, primers for specific nested single
target amplification of the TCR-b gene rearrangements of
three clones identified in brain tissue (CD81 clones 2, 3,
and 8; Table III) were designed. Clone-specific PCR was
established using Jurkat cells stably transfected with a single
copy of either clonal rearrangement. Each set of clone-spe-
cific primers was capable of detecting one single Jurkat
control cell among 103 irrelevant T cells from a healthy do-
nor (described in Materials and Methods), and thus with a
similar sensitivity as the reverse transcriptase PCR–based
spectratyping technique.
102 or 103 CD81CD45RO1 cells (expanded CD81 T cell
clones were assumed to belong to the effector/memory
compartment, and thus to be CD45RO1 [38]) from both
blood samples (12 mo and 31 mo) were sorted into each of
several PCR tubes. 104 cells were analyzed in total for each
clone and time point. The V region sequence of clone 8 was
amplified from 6 of 10 and 8 of 10 samples of 103 cells
(blood samples 12 mo and 31 mo, respectively) and from 2
of 20 samples containing 102 cells (sample 31 mo; Table V).
PCR products were shown to represent the clonal V region
sequences by sequencing. This indicates that the frequency
of clone 8 was z1 in 103 peripheral blood CD81CD45RO1
T cells at both time points analyzed. The clonal rearrange-
ment of clone 2 was amplified only once from all samples
analyzed, and clone 3 was not found at all (Table V).
Discussion
Clonal composition and TCR repertoire of CD41 and
CD81 T cells infiltrating actively demyelinating brain le-
Figure 2. Detection of clone 10 (identified in brain tissue of case 2) in
peripheral blood T cells by CDR3 spectratyping analysis. mRNA ex-
tracted from FACS®-sorted CD81 T cells was reverse transcribed. TCR-b
cDNA was amplified using 1 Cb- and 26 Vb-specific primers. PCR
products were used as templates in runoff reactions with fluorescently la-
beled Jb-specific primers, and runoff products were analyzed on an auto-
mated DNA sequencer. The products shown were amplified with the
Vb14-Cb primer pair and labeled with an Jb1S1-specific primer in the
runoff reaction. The spectratypes correspond to the blood samples ob-
tained 12 mo (top) and 31 mo (bottom) after brain surgery. The promi-
nent peaks marked by the arrows potentially represented the rearrange-
ment of clone 10 (same V-J combination and CDR3 length). Direct
sequencing of the Vb14-Jb1S1 PCR products resulted in mixed se-
quences that potentially contained the CDR3 sequence of clone 10. The
products were cloned into a plasmid vector. After transformation of
Escherichia coli and sequence analysis of plasmid DNA from bacterial colo-
nies, the V region sequence of clone 10 was identified in 7 of 26 colonies
(“12 months”) and 7 of 12 colonies (“31 months”).
Table V. Detection of Clone 8 (Identified in Brain Tissue of 
Case 2) in Peripheral Blood CD81CD45RO1 T Cells by
Clone-specific PCR
Cell samples
Blood sample;* 
no. of cells per 
PCR tube‡
PCR specific 
for V region of 
clone no.
Analyzed by 
clone-specific 
PCR
Positive for 
specific product
12 mo; 103 2 10 0/10
31 mo; 103 2 10 1/10
12 mo; 103 3 9 0/9
12 mo; 5 3 102 3 1 0/1
12 mo; 102 3 5 0/5
31 mo; 103 3 10 0/10
12 mo; 103 8 10 6/10
31 mo; 103 8 10 8/10
31 mo; 102 8 20 2/20
Each set of primers consisted of the Vb-specific primer and a nested pair
of CDR3-specific primers. The clonal V region sequences were inserted
into plasmid vectors, and the resulting constructs were stably transfected
into Jurkat cells. To positively control single target amplification of the
clonal V region sequence, single Jurkat control cells carrying a single
copy of the respective V region DNA were sorted into tubes containing,
as indicated, 103 or 102 irrelevant CD81CD45RO1 T cells from a
healthy donor. These samples were analyzed in parallel with the T cell
samples from blood of case 2 under identical conditions (results of
control amplifications are discussed in Materials and Methods).
*Obtained at the indicated time points after brain surgery.
‡CD81CD45RO1 T cells sorted by FACS®.401 Babbe et al.
sions in two cases of MS were determined at the level of
single cells. Suitable brain tissue was identified by screening
autopsy and biopsy material of several cases for the presence
of actively demyelinating lesions, using as an indicator the
molecular composition of myelin degradation products in
macrophages and an inflammatory activation marker on the
macrophage surface (3). Active lesions, generally rare in
MS brain material obtained postmortem (5, 13), were de-
tected in material of case 1. A large actively demyelinating
lesion was also found in the biopsy of case 2, which likely
represented an early stage of disease development, as the le-
sion was already resected 2 wk after the first clinical mani-
festation of MS. In this case, it was possible to relate find-
ings in brain tissue to analyses of peripheral blood obtained
after brain biopsy.
Frozen sections were stained for CD4 or CD8. In both
cases, CD81 T cells were far more numerous than CD41 T
cells in the parenchyma of all lesions studied. Some earlier
studies described a preponderance of CD41 over CD81 T
cells in MS lesions, whereas the opposite was reported by
several other groups (13, 14).
Individual CD41 and CD81 T cells were micromanipu-
lated from the stained sections and subjected to single target
amplification of TCR-b gene rearrangements using a com-
plex mixture of Vb- and Jb-specific primers that was
shown previously to reliably amplify the various V-J com-
binations from single cells (20). Amplified V region genes
were directly sequenced. This strategy allows the character-
ization of T cell infiltrates in MS lesions with unprece-
dented resolution. In contrast to approaches based on the
analysis of total RNA extracted from whole tissue speci-
mens (14–17), in this study, sequences could be assigned to
individual T cells in particular locations within the diseased
tissue. Thus, it was possible to differentially investigate the
composition of CD41 and CD81 T cell populations in
perivascular aggregates or the parenchyma of active and in-
active lesions. It should be noted that the combination of
micromanipulation and single target amplification yields
quantitative data, in contrast to semiquantitative reverse
transcriptase PCR–based approaches used previously to
study TCR repertoires in MS lesions (14–17, 39), with the
inherent problems of sequence representation. The fre-
quency of detection of particular gene rearrangements in
our analysis closely parallels the actual representation of the
respective clone in the brain tissue.
Expansions of both CD41 and CD81 T cell clones were
detected in the lesions. In both cases, the majority of the
parenchymal CD81 T cell population was composed of
few clones. A background of polyclonal cells accounted for
only 24–46% of all CD81 cells in the five lesions analyzed.
One CD81 clone (clone 1) was particularly prominent ac-
counting for 35% of the CD81 cells in case 1. Among the
parenchymal CD41 cells of both cases, the fraction of cells
accounted for by oligoclonal expansions was considerably
lower. The majority of rearrangements (68–88%) could not
be assigned to CD41 T cell clones expanded in situ.
The finding of expanded T cell clones in MS lesions
raises the question of their functional properties. CD41 and
CD81 T cells may be involved in pathogenic immune re-
sponses directed against brain autoantigens and cause oligo-
dendrocyte damage by direct cytolysis or cytokine secre-
tion. The pathogenic potential of CD41 T cells specific for
myelin antigens is well established in animal models of de-
myelinating disease (7, 40). Evidence for a pathogenic role
of CD41 T cells in MS was provided by the finding of in-
creased frequencies of activated myelin-reactive T cells in
the CSF of MS patients compared with blood of the pa-
tients or with other neurological diseases (41, 42). Further-
more, the association of MS with particular MHC class II
haplotypes suggests that presentation of antigen to CD41 T
cells may be an important pathogenic event (2, 6). More
recently, the role of CD81 T cells in inflammatory myelin
destruction was addressed in more detail (for a review, see
reference 43). CD81 T cells have been shown to contrib-
ute to tissue injury in animal models of inflammatory de-
myelination (44, 45). CTLs specific for human myelin pro-
teins were detected in blood of MS patients and healthy
individuals (46, 47). Human oligodendrocytes were shown
to be capable of expressing MHC class I in vitro (48, 49)
and to be susceptible to lysis by myelin basic protein–spe-
cific CTLs (47). PLP-specific CD81 T cells were shown to
be capable of secreting proinflammatory chemokines (50)
and of chemoattracting myelin-specific CD41 T cells (51).
In addition to pathogenic autoreactive T cells, MS lesions
may contain T cell clones that do not promote but instead
counteract the destructive process. In EAE, effects of both
CD41 and CD81 regulatory T cells have been described
(44, 52–55).
In addition to autoreactive and regulatory T cell clones,
clones not primarily connected to the autoimmune process
may be present in the brain lesions. Activated T cells have
the capacity to cross the blood–brain barrier and home to
sites of inflammation irrespective of their antigenic specific-
ity (56, 57). Clonal expansions of CD81 T cells were found
in the blood of MS patients (12). However, the fraction of
activated T cells, in particular the activated CD81 subset,
often contains large clonal expansions even in healthy indi-
viduals (36, 58–60). Such oligoclonal expansions may be
stable over years. They are preferentially found in elderly
individuals and may represent chronic T cell responses to
persistent infections (60). In rheumatoid arthritis but also in
arthritis of nonimmunological pathogenesis (arthrosis), ex-
pansions of herpes virus–specific T cells have been detected
in synovial fluid, suggesting that these cells were nonspecif-
ically trapped at the site of inflammation (61). Therefore,
the clonal expansions detected in MS lesions in this study
may comprise clones not originally related to the patho-
genic process.
The distribution of encephalitogenic T cells within cen-
tral nervous system lesions at the peak of disease after in-
duction of EAE by transfer of a myelin basic protein–spe-
cific Vb8.2-expressing T cell line was investigated in Lewis
rats (18, 19). Although Vb8.21 cells constituted a minor
fraction of a/b T cells in the perivascular infiltrates (re-
flecting the low frequency of Vb8.21 cells in the normal
rat T cell repertoire), Vb8.21 cells were enriched among402 Large CD81 T Cell Clones in Multiple Sclerosis Lesions
parenchymal T cells. One could therefore have speculated
that in MS, parenchymal T cells may also differ fundamen-
tally in repertoire and function from T cells in perivascular
infiltrates, with a large fraction of the latter being nonspe-
cifically attracted bystander cells, whereas most encephali-
togenic T cells are located in the parenchyma. However, in
this study, comparison of clonal composition and TCR
repertoire of perivascular versus parenchymal T cells in MS
lesions revealed no striking differences, as members of most
larger clonal expansions were detected in both locations.
The clonal rearrangement of the most prominent expan-
sion in case 1, clone 1 (35% of CD81 T cells), accounted
for a similar fraction of parenchymal and perivascular
CD81 T cells (considering that roughly three quarters of
perivascular T cells were CD81).
Likewise, a comparison of the clonal composition of
CD81 T cells infiltrating an actively demyelinating versus
an inactive lesion did not reveal striking differences except
for a twofold-higher frequency of CD81 clone 1 in the in-
active lesion. Interpretations of this finding may be that
clone 1 was a suppressive clone responsible for the down-
regulation of demyelinating activity in the inactive lesion
(44, 52, 53). Alternatively, it may reflect a concept pro-
posed by Steinman and colleagues (62–64) based on find-
ings in EAE suggesting that pathogenetically relevant T
cells may be encountered more frequently in inactive le-
sions where they may be less diluted by nonspecifically at-
tracted cells.
In case 1, some of the gene rearrangements from CD81
T cells showed sequence similarities that strongly suggested
selection for common peptide specificities. It is tempting to
speculate that these cells were actively involved in the dis-
ease process. However, nonspecific recruitment of T cell
populations selected in responses unrelated to MS patho-
genesis is an alternative explanation (61).
In summary, the T cell infiltrate in MS lesions of two
cases was shown to be dominated by few CD81 clones.
CD41 T cells were generally less numerous and more het-
erogeneous. Nevertheless, some clonal expansions were
also detected in this population. In one case, comparison of
TCR b-V region sequences provided evidence that some
of the CD81 T cells were selected for recognition of com-
mon epitopes. The spatial distribution of members of the
CD41 and CD81 clones within the lesion and between le-
sions differing in demyelinating activity did not provide di-
rect clues to the question of their pathogenetic relevance.
Knowledge of the antigenic specificity of clones expanded
in the brain lesions may help to elucidate their functional
properties. Two of these clones were detected in peripheral
blood of case 2 at two different time points after brain bi-
opsy, one by CDR3 spectratyping, the other by a sensitive
clone-specific PCR. Experiments aiming at the isolation of
these clones by cultivation of CD81 T cells from the blood
of the patient are presently under way. After cloning by
limiting dilution, detection of cells belonging to the clones
in question should be possible by PCR. A complementary
approach applicable to the analysis of clones from both
cases aims at coamplification of both TCR-a and -b gene
rearrangements from individual micromanipulated cells.
Primer sets for the amplification of TCR-a gene rear-
rangements from single cells are currently being established.
Cloning of amplified a and b V region sequences into
TCR expression vectors should allow transfer of clonal re-
ceptor specificities to cell lines and subsequent in vitro
analysis of antigenic specificities.
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